Publications by authors named "M Eisenberger"
Importance: Olaparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that provides benefit in combination with hormonal therapies in patients with metastatic prostate cancer who harbor homologous recombination repair (HRR) alterations. Its efficacy in the absence of androgen deprivation therapy has not been tested.
Objective: To determine the activity of olaparib monotherapy among patients with high-risk biochemically recurrent (BCR) prostate cancer after radical prostatectomy.
Article Synopsis
- High-dose intravenous vitamin C (HDIVC) was tested alongside docetaxel in a clinical trial for patients with advanced prostate cancer, showing no significant benefit compared to docetaxel alone.
- The trial involved 47 participants and measured effectiveness through PSA response rates, overall survival, and quality of life, with similar outcomes in both the HDIVC and placebo groups.
- The study was halted early due to no evidence that HDIVC improved cancer treatment results, suggesting it shouldn’t be routinely used for metastatic castration-resistant prostate cancer.
Cyclic high-dose testosterone administration, known as bipolar androgen therapy (BAT), is a treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we report the results of a multicenter, single arm Phase 2 study (NCT03554317) enrolling 45 patients with heavily pretreated mCRPC who received BAT (testosterone cypionate, 400 mg intramuscularly every 28 days) with the addition of nivolumab (480 mg intravenously every 28 days) following three cycles of BAT monotherapy. The primary endpoint of a confirmed PSA response rate was met and estimated at 40% (N = 18/45, 95% CI: 25.
View Article and Find Full Text PDFObjectives: We evaluated F-DCFPyL test-retest repeatability of uptake in normal organs.
Methods: Twenty-two prostate cancer (PC) patients underwent two F-DCFPyL PET scans within 7 days within a prospective clinical trial (NCT03793543). In both PET scans, uptake in normal organs (kidneys, spleen, liver, and salivary and lacrimal glands) was quantified.
Objective: The aims of this study were to investigate the utility of [F]F-Florastamin, a novel prostate-specific membrane antigen (PSMA)-targeted PET radiotracer with facile radiochemistry, relative to the conventional imaging for the detection of sties of disease and evaluate the effect of multi-timepoint imaging with [F]F-Florastamin PET on lesion detectability.
Methods: Eight prostate cancer patients with known or suspected recurrence who underwent [F]F-Florastamin PET/CT at 1-h and 2-h imaging time-points were included in this prospective pilot study. [F]F-Florastamin PET images were interpreted visually and quantitatively at both time points and compared with CIM.